Get the Stockscreener App
67.69
0.25%
-0.17
Pre-market:
28.30
-39.39
-58.19%
Uniqure N V stock is traded at $67.69, with a volume of 889.93K.
It is down -0.25% in the last 24 hours and up +15.97% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$67.86
Open:
$68
24h Volume:
889.93K
Relative Volume:
0.28
Market Cap:
$3.71B
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-17.27
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
+10.95%
1M Performance:
+15.97%
6M Performance:
+358.60%
1Y Performance:
+1,083%
1-Day Range:
$66.00
$68.62
1-Week Range:
$61.30
$71.50
52-Week Range:
$5.35
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
67.69 | 4.18B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure stock plummets after FDA shifts stance on Huntington’s therapy By Investing.com - Investing.com South Africa
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - Yahoo! Finance Australia
Can uniQure N.V. stock hit record highs again2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Risk adjusted return profile for uniQure N.V. analyzedEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
What catalysts could drive uniQure N.V. stock higherMarket Activity Recap & Community Verified Watchlist Alerts - newser.com
uniQure N.V. stock outlook for YEAREarnings Summary Report & Weekly Market Pulse Updates - newser.com
Can uniQure N.V. stock hit analyst price targetsTrade Risk Assessment & Long Hold Capital Preservation Plans - newser.com
Jennison Associates LLC Acquires Shares of 140,060 uniQure N.V. $QURE - MarketBeat
What data driven models say about uniQure N.V.’s future2025 Price Action Summary & Safe Entry Trade Reports - newser.com
How analysts rate uniQure N.V. stock todayQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
What analysts say about uniQure NV UQ1 stockInflation Impact on Stocks & Breakout Portfolio Performance - earlytimes.in
How institutional buying supports uniQure N.V. stock2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Is uniQure N.V. stock trading at a premium valuation2025 Volume Leaders & Safe Capital Growth Trade Ideas - newser.com
Is uniQure N.V. stock a bargain at current levelsJuly 2025 Levels & Risk Managed Investment Signals - newser.com
How to read the order book for uniQure N.V.Bond Market & Safe Capital Investment Plans - newser.com
Is uniQure N.V. (UQ1) stock a top dividend aristocrat candidate2025 Market Overview & Consistent Income Trade Ideas - newser.com
Applying Wyckoff theory to uniQure N.V. stockRate Hike & High Accuracy Buy Signal Tips - newser.com
Using Bollinger Bands to evaluate uniQure N.V.Bear Alert & Low Risk High Win Rate Stock Picks - newser.com
Will uniQure N.V. stock benefit from automationJuly 2025 Review & Real-Time Market Sentiment Alerts - newser.com
uniQure N.V. (QURE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
How uniQure N.V. stock reacts to job market dataJuly 2025 Earnings & Real-Time Sentiment Analysis - newser.com
uniQure (NASDAQ:QURE) Hits New 1-Year HighShould You Buy? - MarketBeat
uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade) - Seeking Alpha
uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Uniqure stock hits 52-week high at 65.19 USD By Investing.com - Investing.com Australia
uniQure (QURE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Sep 24 '25 |
Sale |
41.46 |
226,316 |
9,382,473 |
651,454 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Option Exercise |
5.37 |
15,000 |
80,550 |
232,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Option Exercise |
13.03 |
3,000 |
39,090 |
220,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Sale |
55.00 |
15,000 |
825,000 |
217,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Sale |
40.04 |
3,000 |
120,120 |
217,730 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):